Literature DB >> 8312659

Diseases among men living in human T-lymphotropic virus type I endemic areas in Japan.

T Matsuzaki1, H Otose, K Hashimoto, Y Shibata, K Arimura, M Osame.   

Abstract

The health effects of human T-lymphotropic virus type I (HTLV-I) were studied in HTLV-I endemic areas in Japan during the period from September 1990 to October 1991. The study subjects were 2,847 men living in the southern part of Kyushu and engaged in light work. Ages ranged from 19 to 79 years (47.8 +/- 7.2; mean +/- standard deviation). The prevalence of each disturbance was analyzed with a logistic model. The disturbances in which the prevalence showed a significant association with HTLV-I were old tuberculosis, ulcerative colitis and ossification of the posterior longitudinal ligament of the cervical spine (OPLL). The results of the present study suggest that HTLV-I may be a risk factor for these diseases and may indicate the necessity for a synthetic study on HTLV-I.

Entities:  

Mesh:

Year:  1993        PMID: 8312659     DOI: 10.2169/internalmedicine.32.623

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Clinical investigation of pulmonary Mycobacterium avium complex infection in human T lymphotrophic virus type I carriers.

Authors:  W Matsuyama; A Mizoguchi; F Iwami; Y Koreeda; J Wakimoto; H Kanazawa; S Mori; M Kawabata; H Fukunaga; M Osame
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

3.  Immunocytochemical localization of the endogenous neuroexcitotoxin quinolinate in human peripheral blood monocytes/macrophages and the effect of human T-cell lymphotropic virus type I infection.

Authors:  C N Venkateshan; R Narayanan; M G Espey; J R Moffett; D C Gajdusek; C J Gibbs; M A Namboodiri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

4.  HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru.

Authors:  K Verdonck; E González; W Schrooten; G Vanham; E Gotuzzo
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

5.  Predicting and Designing Epitope Ensemble Vaccines against HTLV-1.

Authors:  Saruar Alam; Md Kamrul Hasan; Omar Hamza Bin Manjur; Akib Mahmud Khan; Zinat Sharmin; Mahmud Arif Pavel; Md Faruk Hossain
Journal:  J Integr Bioinform       Date:  2020-01-08

Review 6.  Human T-cell leukaemia virus type 1 associated pulmonary disease: clinical and pathological features of an under-recognised complication of HTLV-1 infection.

Authors:  Lloyd Einsiedel; Fabian Chiong; Hubertus Jersmann; Graham P Taylor
Journal:  Retrovirology       Date:  2021-01-06       Impact factor: 4.602

Review 7.  HTLV-1 and Co-infections.

Authors:  Carolina Rosadas; Graham P Taylor
Journal:  Front Med (Lausanne)       Date:  2022-02-03

8.  Immune Compromise in HIV-1/HTLV-1 Coinfection With Paradoxical Resolution of CD4 Lymphocytosis During Antiretroviral Therapy: A Case Report.

Authors:  N Rockwood; L Cook; H Kagdi; S Basnayake; C R M Bangham; A L Pozniak; G P Taylor
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Human T-lymphotropic virus 1aA circulation and risk factors for sexually transmitted infections in an Amazon geographic area with lowest human development index (Marajó Island, Northern Brazil).

Authors:  Samantha Assis de Aguiar; Samires Avelino de Souza França; Barbara Brasil Santana; Mike Barbosa Santos; Felipe Bonfim Freitas; Glenda Ferreira; Izaura Cayres-Vallinoto; Marluísa O G Ishak; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  BMC Infect Dis       Date:  2017-12-08       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.